Aktis Oncology is developing cancer radiation treatments intended to more precise and potent compared to other radiotherapies. The startup is now out of stealth with $72 million in Series A financing.
Bluebird bio said independent analyses found that the gene therapy inserted its payload at a site not known to cause cancer. Based on the results, CEO Nick Leschly said the company has asked the FDA for permission to resume the three clinical trials that were placed on hold in February during the inquiry.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Base-editing biotech Beam Therapeutics engineered an all-stock buyout of Guide Therapeutics, a startup that finds, in vivo, the lipid nanoparticles that can deliver genetic medicines. Beam said GuideTx’s tech helps it address tissue types throughout the body, not just the liver.
Cancer is a known risk of lentiviral-based gene therapies. Though bluebird says its gene therapy is engineered to avoid that risk, the company is suspending two clinical trials pending the outcome of its inquiry.
One year after losing Merck as a partner, KalVista reports mid-stage clinical data for a pill that could offer an alternative to injectable drugs for a rare, potentially life-threatening disease. KalVista plans to meet with the FDA about proceeding to a Phase 3 study.
Massachusetts-based Be Biopharma will use the proceeds to build a team as it seeks to develop B-cell therapies for a variety of diseases.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.
Deborah DiSanzo, who has served as general manager of IBM Watson Health since 2015, is stepping down from her position and heading to the strategy team for IBM Cognitive Solutions, according to STAT.
Qiming Venture Partners led the Series B round, which also saw participation from Salesforce Ventures, Experian Ventures and The PNC Financial Services Group.
On the back of that symbolic FDA approval, Foundation Medicine's Gaurav Singal discussed the latest innovations for expanding access to precision medicine beyond the major academic centers.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
A recent poll from PatientsLikeMe asked 2,755 patients with chronic or progressive degenerative conditions about their thoughts on healthcare in America.
Seres Therapeutics had a rough 2016, but it's optimistic that those hard-earned lessons could now help it succeed. Following discussions with FDA, it has moved into a pivotal Phase 3 trial in recurrent C. difficile infections.
With a fresh financing from a Series B, Bicycle Therapeutics needs to begin translating its high-potential peptide-based platform into a portfolio of clinically-proven drugs.
Selling physician-ordered carrier screening kits on Amazon may not seem like a logical fit, but there are a number of benefits that Good Start Genetics is now tapping into.
Investors, including Ali Baba billionaire Jack Ma, have cut a fresh check for WuXi NextCODE to the tune of $75 million. The Shanghai-based genomics specialist has a wide range of international services and new consumer products for the Chinese market.